Pool | Vol. | Vaccine | 15mer peptide | AA no. | Sequence | Pool sfc/m | 15mer sfc/m | Percent of pool |
---|---|---|---|---|---|---|---|---|
Cp1 | 58 | Ad-C | C3 | 9-23 | SVSSFLFVEALFQEY | 116 | 29 | 25.0 |
Cp1 | 05 | Ad-CA | C3 | Â | SVSSFLFVEALFQEY | 142 | 65 | 45.8 |
Cp1 | 69 | Ad-C | C3 | Â | SVSSFLFVEALFQEY | 411 | 385 | 93.7 |
Cp1 | 12 | Ad-CA | C4 | 13-27 | FLFVEALFQEYQCYG | 64 | 87 | 135 |
Cp1 | 05 | Ad-CA | C4 | Â | FLFVEALFQEYQCYG | 142 | 44 | 31.0 |
Cp1 | 01 | Ad-CA | C4 | Â | FLFVEALFQEYQCYG | 77 | 48 | 62.3 |
Cp1 | 69 | Ad-C | C4 | Â | FLFVEALFQEYQCYG | 411 | 368 | 89.5 |
Cp1 | 58 | Ad-C | C5 | 17-31 | EALFQEYQCYGSSSN | 116 | 105 | 90.5 |
Cp1 | 58 | Ad-C | C6 | 21-35 | QEYQCYGSSSNTRVL | 116 | 83 | 71.6 |
Cp2 | 49 | Ad-C | C8 | 29-43 | SSNTRVLNELNYDNA | 64 | 41 | 64.1 |
Cp2 | 41 | Ad-C | C10 | 37-51 | ELNYDNAGTNLYNEL | 83 | 35 | 42.2 |
Cp2 | 49 | Ad-C | C12 | 45-59 | TNLYNELEMNYYGKQ | 64 | 28 | 43.8 |
Cp2 | 12 | Ad-CA | C12 | Â | TNLYNELEMNYYGKQ | 331 | 411 | 124 |
Cp2 | 01 | Ad-CA | C12 | Â | TNLYNELEMNYYGKQ | 119 | 119 | 100 |
Cp2 | 01 | Ad-CA | C13 | 49-63 | NELEMNYYGKQENWY | 119 | 116 | 97.5 |
Cp2 | 12 | Ad-CA | C13 | Â | NELEMNYYGKQENWY | 331 | 334 | 100 |
Cp6 | 61 | Ad-C | C47 | 313-327 | DKHIKEYLNKIQNSL | 53 | 48 | 90.6 |
Cp6 | 41 | Ad-C | C48 | 317-331 | KEYLNKIQNSLSTEW | 95 | 103 | 108 |
Cp6 | 05 | Ad-CA | C48 | Â | KEYLNKIQNSLSTEW | 130 | 106 | 81.5 |
Cp6 | 58 | Ad-C | C48 | Â | KEYLNKIQNSLSTEW | 24 | 45 | 187 |
Cp9 | 61 | Ad-C | C60 | 365-379 | EKKICKMEKCSSVFN | 128 | 39 | 30.5 |
Cp9 | 01 | Ad-CA | C62 | 373-387 | KCSSVFNVVNSSIGL | 39 | 116 | 297 |
Cp9 | 08 | Ad-CA | C63 | 377-391 | VFNVVNSSIGLIMVL | 142 | 109 | 76.8 |
Cp9 | 08 | Ad-CA | C64 | 381-395 | VNSSIGLIMVLSFLF | 142 | 91 | 64.1 |
Cp9 | 01 | Ad-CA | C65 | 383-397 | SSIGLIMVLSFLFLN | 39 | 46 | 117 |
Cp9 | 02 | Ad-CA | C65 | Â | SSIGLIMVLSFLFLN | 16 | 44 | 275 |
Cp9 | 08 | Ad-CA | C65 | Â | SSIGLIMVLSFLFLN | 142 | 62 | 43.7 |